Niagen Bioscience (NAGE) Operating Income (2010 - 2026)
Niagen Bioscience (NAGE) reported Operating Income of $1.6 million for Q1 2026, down 66.97% year-over-year from $4.8 million in Q1 2025, and down 61.43% quarter-over-quarter from $4.1 million in Q4 2025.
Niagen Bioscience (NAGE) Operating Income (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 17 years of Operating Income data on file, last reported at $1.6 million in Q1 2026.
- Operating Income for Q1 2026 came in at $1.6 million, down 66.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.1 million (down 1.1% YoY), and the FY2025 annual result was $16.3 million, up 110.7% from the prior year.
- Operating Income slipped to $1.6 million in Q1 2026 per NAGE's latest filing, from $4.1 million in the prior quarter.
- Over five years, Operating Income peaked at $7.1 million in Q4 2024 and troughed at -$7.7 million in Q1 2022.
- A 5-year average of $79647.1 and a median of -$256000.0 in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2024 and 2026: Operating Income jumped 4332.74% in 2024, then plunged 66.97% in 2026.
- A 5-year view of Operating Income shows it stood at -$1.4 million in 2022, then surged by 88.37% to -$168000.0 in 2023, then jumped by 4332.74% to $7.1 million in 2024, then tumbled by 42.54% to $4.1 million in 2025, then sank by 61.43% to $1.6 million in 2026.
- Business Quant data shows NAGE's Operating Income at $1.6 million in Q1 2026, $4.1 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -65.83 Mn |
| 10 | Niagen Bioscience | 280.11 Mn | 213.56 Mn | 19.98 Mn | 1.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.58 Mn |
| Dec 31, 2025 | 4.09 Mn |
| Sep 30, 2025 | 4.24 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Mar 31, 2025 | 4.77 Mn |
| Dec 31, 2024 | 7.11 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | -256,000.00 |
| Mar 31, 2024 | -731,000.00 |
| Dec 31, 2023 | -168,000.00 |
| Sep 30, 2023 | -1.15 Mn |
| Jun 30, 2023 | -2.32 Mn |
| Mar 31, 2023 | -1.97 Mn |
| Dec 31, 2022 | -1.44 Mn |
| Sep 30, 2022 | -3.07 Mn |
| Jun 30, 2022 | -6.39 Mn |
| Mar 31, 2022 | -7.73 Mn |
| Dec 31, 2021 | -5.32 Mn |
| Sep 30, 2021 | -8.84 Mn |
| Jun 30, 2021 | -5.55 Mn |